Search research articles
Contact Us
Filters
Showing results (601-610 of 745) with videos related to
Page
of 75
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Jürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Journal of Cancer Research and Clinical Oncology
|
December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Roberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.
Frontiers in Oncology
|
April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Cancers
|
November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe
Michael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Journal for Immunotherapy of Cancer
|
February 22, 2019
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Mirjam Fässler, Stefan Diem, Joanna Mangana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.
Page
of 75
Search research articles
Search
Showing results (601-610 of 745) with videos related to
Sort By:
Page
of 75
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Jürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Journal of Cancer Research and Clinical Oncology
|
December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Roberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.
Frontiers in Oncology
|
April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Cancers
|
November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe
Michael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Journal for Immunotherapy of Cancer
|
February 22, 2019
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Mirjam Fässler, Stefan Diem, Joanna Mangana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.
Page
of 75